Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NYSE:NVS is in a personal buy zone.
Target #1 = $110.00
Target #2 = $120.00
Pharmaceuticals
Can a Pharmaceutical Giant Rewrite Its Own Destiny?In the complex world of global pharmaceuticals, Teva Pharmaceutical Industries Ltd. emerges as a compelling narrative of strategic reinvention. Under the leadership of CEO Richard Francis, the company has transformed from a struggling enterprise to a potential market leader, executing a bold "Pivot to Growth" strategy that has captured the attention of investors and industry experts alike. The company's remarkable journey reflects corporate resilience and a profound understanding of how strategic focus and innovative thinking can resurrect a seemingly faltering business.
Teva's renaissance is characterized by calculated moves that challenge traditional pharmaceutical business models. By strategically divesting its Japanese joint venture, selectively targeting high-potential generic markets, and developing promising drug candidates like Anti-TL1A, the company has demonstrated an extraordinary ability to reimagine its core strengths. The financial metrics tell a compelling story: a 66% market capitalization increase, double-digit revenue growth, and a strategic pipeline that promises future innovation in critical therapeutic areas such as neurology and digestive system treatments.
Beyond financial metrics, Teva represents a broader narrative of corporate transformation that extends beyond balance sheets. Its commitment to patient access programs, such as the recent inhaler donation initiative with Direct Relief, reveals a deeper organizational philosophy that intertwines strategic growth with social responsibility. This approach challenges the traditional perception of pharmaceutical companies as purely profit-driven entities, positioning Teva as a forward-thinking organization that understands its broader role in global healthcare ecosystems.
The company's journey poses a provocative question to business leaders and investors: Can strategic vision, relentless innovation, and a commitment to patient care truly redefine a corporation's trajectory? Teva's emerging story suggests that the answer is a resounding yes—a testament to the power of adaptive strategy, visionary leadership, and an unwavering commitment to pushing the boundaries of what's possible in the pharmaceutical landscape.
Can Pharma Innovation Rewrite Healthcare's Future?In the rapidly evolving landscape of medical technology, Eli Lilly emerges as a beacon of transformative potential, challenging conventional boundaries of pharmaceutical innovation. With a strategic masterstroke, the company has positioned itself at the forefront of medical breakthroughs, particularly in the revolutionary realm of weight loss and diabetes treatments. The remarkable Zepbound medication stands as a testament to this vision, demonstrating unprecedented efficacy by enabling patients to lose an average of 20.2% body weight - a figure that not only surpasses competitors but also represents a paradigm shift in medical intervention.
The company's financial architecture is equally compelling, reflecting a meticulously crafted approach to growth and shareholder value. With a staggering market capitalization of $722 billion, a 27.4% revenue growth, and an impressive 80.9% gross profit margin, Eli Lilly transcends the traditional pharmaceutical business model. Its recent $15 billion share buyback program and consistent 54-year dividend payment history underscore a strategic philosophy that balances aggressive innovation with prudent financial management, creating a blueprint for sustainable corporate success.
Beyond financial metrics and breakthrough medications, Eli Lilly represents something more profound: a vision of healthcare's future where technology, research, and human potential converge. The company's $3 billion manufacturing expansion, commitment to oncology research with drugs like Jaypirca, and continuous investment in cutting-edge medical solutions paint a picture of an organization that sees beyond immediate profit - an entity committed to reshaping human health through relentless innovation and scientific excellence. In an era of unprecedented medical challenges, Eli Lilly stands not just as a pharmaceutical company, but as a harbinger of hope, demonstrating how visionary thinking can transform global health landscapes.
Lupin Long-Term Investment IdeaAs we can see on the month chart stock breakout it rounding bottom after a many years with very good volume and retesting. Bullish crossover on November 2023
Technical Analysis & indicators 🔍
Monthly Chart
Rounding Bottom
Educational content 📖
This stock analysis is designed for educational purposes and should not be taken as financial advice. Please carry out your own research or consult with a financial advisor before investing.
Visit the website and check fundamental
ELI LILLY: This consolidation is a buy opportunity.Eli Lilly is neutral on its 1D technical outlook (RSI = 52.880, MACD = 1.910, ADX = 25.797) as well as on 1W as for the past 7 weeks it has turned sideways. This consolidation is taking place half-way through the new bullish wave of the Channel Up that started in early 2023. As you see it is supported by the 1W MA50 and every bullish wave in the beginning was almost at +50% but the latest one was +35%. Consequently we expect a minimum of +46.22% from the bottom and that's what we're aiming for (TP = 1,095).
See how our prior idea has worked out:
## If you like our free content follow our profile to get more daily ideas. ##
## Comments and likes are greatly appreciated. ##
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry.
Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended.
The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
Alembic Pharma-Bullish view- Short to Medium term analysis NSE:APLLTD
09.09.2024
Buy-1203
Target 1- 1282
Target 2-1575
Stop Loss- 1020
Risk Reward- 1:2
Holding period- 3 to 6 Months
Very good fundamentals along with below technical analysis
1.Inside bar breakout in weekly TF
2.Trend- Continues uptrend from last one year
3.Price has taken retracement at very strong key level
4.Gradual increase in volumes.
5. Very strong rejection from FVG
Flag pattern Breakout in Pharma IndexIndices are far more reliable during technical analysis as compared to the individual stocks.
The pattern is a clean one in Nifty Pharma Index.
This is to spread the awareness about technical chart patterns and not a buy/sell recommendation.
Always do your own research before making any financial decision.
Sanofi (SNY): A Strong Investment CaseCompany Overview:
Sanofi NASDAQ:SNY is a major pharmaceutical company based in Paris, with a market capitalization of $134 billion.
Investment Highlights:
Dividend Yield: 3.8%, more than double the S&P 500 average.
Drug Portfolio: Diverse and includes successful drug developments.
Pipeline: Promising future drug pipeline with potential for growth.
Berkshire Hathaway Investment: Long-standing investment from Berkshire Hathaway underscores the company’s attractiveness and stability.
Outlook:
We are bullish on SNY due to its growth potential and solid dividend payout. The combination of a strong drug portfolio, promising pipeline, and robust dividend makes Sanofi a compelling investment choice.
#Sanofi #SNY #Pharmaceuticals #Investment #DividendYield #MarketCap #GrowthPotential #BerkshireHathaway #StockAnalysis #Bullish
ELI LILLY Recovered all losses from its High! What's next?Eli Lilly and Company (LLY) posted a miraculous bullish reversal in the past 2 weeks, recovering yesterday all of the losses of the brutal correction since its July 15 All Time High. Having rebounded on its 1D MA200 (orange trend-line) while the 1D RSI touched the 30.00 oversold barrier for the first time since February 28 2023, we can claim that LLY's Channel Up now sets eyes for its next Higher High.
This pattern is best illustrated with the use of the Fibonacci Channel levels. After initially holding the 1.0 Fib as Resistance, the 'ceiling' is now the 1.5 Fib extension, basically has been since September 12 2023.
The interesting parameter of this pattern is that every approximately +35.00 to +40.00% rise, the price pulls back or turns sideways (red arc pattern) until it eventually hits the 1D MA50 (blue trend-line).
As the stock completes a +35% rise from the bottom, a little above the 1000 mark, we expect it to turn sideways at best. The target after that is $1200, exactly on the 1.0 Fibonacci level, which is still a modest one, considering that the ceiling is now the 1.5 Fib extension, as discussed above.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
Axsome Therapeutics - A Pennant Primed to RiseAxsome - NASDAQ:AXSM
✅In position since Feb 2023 with average price $50.00 per share. This is a long term 3 - 5 year hold.
✅ Current unrealized gain at 75%
✅ Stop Loss set at $63.80 for 50% of the position to ensure short term gain capture
⏳We awaiting increasing levels of volume (see the green zone). Volume moving into this zone would be ideal and demonstrate increased interest
⏳The On Balance Volume (OBV) has demonstrated that is consolidates in parallel channels and when it breaks out of them it signals price direction. We can watch the OBV for direction
The chart still looks great and we are sitting in a nice profit position with short term profits guaranteed by a stop. The OBV will be key to watch. I still think this company is ripe for a buy out.
Background of Axsome Therapeutics
AXSM are a Small Bio-Pharma company with market cap of $4.24 Billon.
In August 2022 Auvelity Anti-Depressants was FDA approved & is the only rapid-acting oral medicine for MDD with labelling describing statistically significant antidepressant efficacy by one week.
AXSM received Breakthrough Therapy designation from the FDA for an Alzheimer's disease drug development and are at the NDA phase for developing a drug for acute treatment of migraine.
AXSM are also developing a treatment for narcolepsy and separately for fibromyalgia.
All in, AXSM's offerings are building momentum. They have developed the fastest acting anti-depressant drug and are bringing it to market, and have a four other drugs in development, all of which have a large patient base. The company would be ripe for a buyout.
PUKA
Momentum Trading Picks:Pharma Stock Ipca LabThe chart presented here is a daily chart, detailing precise entry and stop-loss levels. However, upon examining the weekly chart, a breakout of the cup pattern becomes evident. The target for this pattern is determined by the depth of the cup, making it a compelling long-side investment. The projected target is approximately 700 points higher, suggesting that the price could reach the 2000 rupee level.
SWING IDEA - GLAXO SMITHKLINE PGlaxoSmithKline Pharmaceuticals , a major player in the pharmaceutical industry, is displaying technical signals that suggest a potential swing trade opportunity.
Reasons are listed below :
Breakthrough of Strong Resistance (1800-1900) : The 1800-1900 range was a significant resistance level. The price has broken through, retested, and is now making new highs, indicating strong bullish momentum.
Breaking a 9+ Year Consolidation Phase : The stock has emerged from a consolidation phase that lasted over 9 years, signaling a potential new long-term bullish trend.
Bullish Engulfing Candle on Weekly Timeframe : The recent bullish engulfing candle on the weekly chart indicates a significant shift towards bullish sentiment, engulfing the previous week's candle and suggesting further upward movement.
0.5 Fibonacci Support : The stock has found support at the 0.5 Fibonacci retracement level, reinforcing the potential for a continued bullish trend after a retracement.
Increased Volumes : A noticeable increase in trading volumes confirms the strength of the price move, indicating strong investor interest and participation in the current trend.
Trading at All-Time High : The stock is trading at its all-time high, suggesting strong market confidence and the potential for further gains. However, it's also important to monitor for signs of overextension or profit-taking at these levels.
Target - 2940 // 3600
Stoploss - weekly close below 1950
DISCLAIMER -
Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services.
@visionary.growth.insights
Momentum Trading Picks - Pharma Stock Natco Pharma.This chart is very interesting as well as confusing at the same time for some people let's break it down step by step.
If you see the monthly chart of Natco Pharma you will notice many patterns there like:-
Cup pattern
W pattern
Pole and flag Pattern
Volume is increasing significantly on the monthly chart
Breakout already happened last week but those who are willing to take risks can still participate in it because the stop loss will be a bit on the higher side.
Index to watchout for next week: Pharma Index. For the past few weeks we have been trying to understand how to use the performance of an index reflects in performance of stocks that are constituents of that particular index and vice versa. By catching the index that is on the verge of breaking out or has broken out during the week, we can plan our investment and trades around it to maximize our returns. We spoke about Bank Nifty, then IT Index. Both gave considerable returns in the last 2 /3 weeks. The index that look most interesting this week end is Pharma Index.
Pharma index has given a powerful breakout and has closed above very important fibonacci resistance (20380) this week. The closing of Pharma index this week was 20453.85. The next 2 Fibonacci resistances for Nifty will be at 21013 and 21475. Supports for the Pharma index remain at 19936 and 19397. 19397 is a mega support which has a combined power of Fibonacci, Mid-channel and 50 days EMA.
The stocks that constitute the Pharma index are: Lupin, Dr.Reddy's Lab, Torrent Pharma, Alkem Lab, Biocon, Divi's Lab, Sun Pharma, Cipla, Zydus Life and Aurobindo Pharma. Some Peripheral Pharma stocks can also be looked at for investment purpose. We are not giving a buy or sell call on any of these companies. This is just an educational article explaining the potential moves of Pharma Index, how it can move in either direction and what can be the technical reasons behind the same.
Disclaimer: There is a chance of biases including confirmation bias, information bias, halo effect and anchoring bias in this write-up. Investment in stocks, derivatives and mutual funds is subject to market risks, please consult your investment advisor before taking financial decisions. The data, chart and other information provided above is for the purpose of analysis and is purely educational in nature. The names of the stocks or index levels mentioned in the article are for the purpose of education and analysis only. Purpose of this article is educational. Please do not consider this as a recommendation of any sorts.
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896 and has had consistent growth over the economic cycles. Return on equity has been averaging 40% and although margins have compressed in recent years the company remains highly profitable and in a stable leverage position.
Valuation: With a price to earnings of 20 and price to cash flow of 15 if looks potentially undervalued. I like companies that have a return on equity double that of the price to earnings, and that rule of thumb is met in this case.
Summary: Roche looks like a quality company to potentially take some profits and diversify from my NASDAQ:SIGA position. However, for now it will stay on the watch list. I will be looking at OANDA:USDCHF as well as the valuation metrics I mentioned above.
Here on my macroeconomic and current research shortlist watchlists:
www.tradingview.com
www.tradingview.com
Thanks for reading, have a good one
GILD will be selected for the new Tamiflu vaccine for Pandemic2It's no secret the elite are manufacturing pandemics to herd, destroy and remake society into a neofeudal system controlled by social credit scores. The next pandemic will be H1N1 which has already been shared within the news that milk in the markets has trace amounts of (no worry they say!).
After the establishment rolls out bird-flu for everyone's summer bingo card - Gilead Sciences, the only company that manufactures Tamiflu with options, will be selected to mass create these new vaccines.
The call options on this company are going crazy right now, July, August have a ton of OTM calls being bought, almost like someone is expecting this company to get the greenlight on something major. You could effectively buy .05 OTM calls on this company, but I'd wait a little longer. The TTM squeeze shows the last leg down is being finished. If the market's capitulate a little more, this would be a perfect time to buy those calls for this company.
#PHA/USDT#PHA
The price is moving in a bearish channel pattern on the 4-hour frame, and it adheres to it well, and it is expected to break to the upside
The price rebounded well from the lower border of the channel at the green support level 0.1650, which is a strong level.
We have a tendency to stabilize above the Moving Average 100
We have oversold resistance on the RSI indicator to support the rise, with a downtrend about to break higher
Entry price is 0.1900
The first target is 0.2330
The second target is 0.2600
The third goal is 0.2884
PIRAMAL PHARMA - SUPPLY ZONE BREAKOUT FOR SWING TRADINGSUPPLY ZONE & 5 MONTHS BREAKOUT
Breakout point - 150
ENTRY - 150
SL - 137
TARGETS - 165, 180
Disclaimer - All information on this page is for educational purposes only,
we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made.
UPDATE: Target Reached Aspen R206.03 - Next target higherSymmetrical Triangle was a a text book trade. The previous trend was up. Price broke above the apex 3/4s in and the momentum continued up.
We had further indicators of confirmation for upside to come.
Price>20
Price>200
Target 1 R206.03
So what now? Well we can expect somewhat a consolidation, and a potential Cup and Handle to form. Then we have the next target above R221.
It might be messy to buy now, but in good time it should present a great opportunity. I'll let you know.
Amylyx Stock Down With Over 82%, After Pivotal ALS Drug FailureAmylyx stock ( NASDAQ:AMLX ) crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study.
Patients who received Amylyx Pharmaceuticals' ( NASDAQ:AMLX ) Relyvrio showed no significant difference across multiple markers measuring the severity of amyotrophic lateral sclerosis, the longhand name for ALS. In this disease, nerve cells break down, reducing muscle function.
The Food and Drug Administration approved Relyvrio based on a single study in September 2022. But Amylyx ( NASDAQ:AMLX ) continued on with a Phase 3 study. Now, Amylyx ( NASDAQ:AMLX ) is deciding whether to voluntarily pull the drug from the market in the U.S. and Canada. In Canada, it sells under the brand name Albrioza.
Technical Analysis
On today's stock market, Amylyx ( NASDAQ:AMLX ) stock plummeted 82.9% to 3.36. Shares undercut their 50-day and 200-day moving averages, MarketSurge.com shows. That put shares at a record low.
Way Forward For Amylyx Stock?
It's important to note that Relyvrio failed to make a difference across multiple measures, including the key goal of the study: improvement on the revised Amyotrophic Lateral Sclerosis Functional Rating Scale. The company tested Relyvrio over 48 weeks. Secondary measures of the study also flopped.
Amylyx ( NASDAQ:AMLX ) says it now expects to have the results of its study in Wolfram syndrome patients in the second quarter.